New Insights Into Cancer-Associated Thrombosis
- 1 March 2009
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 29 (3), 316-320
- https://doi.org/10.1161/atvbaha.108.182196
Abstract
Venous thromboembolism (VTE) is an increasingly frequent complication of anticancer therapy. The underlying mechanisms are not completely understood, but are related in part to oncogene activation and tissue factor (TF) expression. Several risk factors have been identified including site and stage of cancer, patient comorbidities, and specific therapeutic agents. Candidate biomarkers such as blood counts, TF, and P-selectin have recently been identified. A risk model predictive of chemotherapy-associated VTE has been validated. Thromboprophylaxis with low molecular weight heparin (LMWH), unfractionated heparin (UFH), or fondaparinux is recommended for hospitalized medical and surgical cancer patients. Long-term anticoagulation with LMWH is safe and effective in reducing recurrent VTE in cancer. The role of thromboprophylaxis in ambulatory cancer patients receiving chemotherapy is an area of active investigation.Keywords
This publication has 64 references indexed in Scilit:
- Blood Transfusions, Thrombosis, and Mortality in Hospitalized Patients With CancerArchives of Internal Medicine, 2008
- Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancerJournal of Thrombosis and Haemostasis, 2008
- Low-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a cochrane systematic reviewJournal of Experimental & Clinical Cancer Research, 2008
- Development and validation of a predictive model for chemotherapy-associated thrombosisBlood, 2008
- Trousseau's syndrome: multiple definitions and multiple mechanismsBlood, 2007
- Microparticle‐associated tissue factor activity: a link between cancer and thrombosis?Journal of Thrombosis and Haemostasis, 2007
- Tissue factor expression as a possible determinant of thromboembolism in ovarian cancerBritish Journal of Cancer, 2007
- Effects of the chemotherapeutic agent doxorubicin on the protein C anticoagulant pathwayMolecular Cancer Therapeutics, 2006
- A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical PatientsThe New England Journal of Medicine, 1999
- Modulation of tissue factor on human monocytes by cisplatin and adriamycinBritish Journal of Haematology, 1992